Previous Close | 1.6800 |
Open | 1.6300 |
Bid | 1.5500 x 1100 |
Ask | 1.7400 x 1100 |
Day's Range | 1.6000 - 1.8300 |
52 Week Range | 1.0900 - 22.1550 |
Volume | |
Avg. Volume | 96,919 |
Market Cap | 57.389M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2040 |
Earnings Date | Aug 09, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for INKT
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000 patients/yearAgenT-797 for the treatment of infections and viral ARDS identified as selectable for funding by DARPA; contract negotiations underway NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK Therape
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will attend the BTIG 2022 Biotechnology Conference. MiNK will participate virtually and host one-on-one meetings with investors on August 8th and 9th. About MiNK Therape
Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ETNEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9th, 2022. MiNK leadersh